News | October 25, 2024
Mankind Pharma completes acquisition of BSV
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Subscribe To Our Newsletter & Stay Updated
